Mostrar el registro sencillo del ítem
dc.contributor.author | Piña, María Jesús | |
dc.contributor.author | Girotti ., Alessandra | |
dc.contributor.author | Santos García, María Mercedes | |
dc.contributor.author | Rodríguez Cabello, José Carlos | |
dc.contributor.author | Arias Vallejo, Francisco Javier | |
dc.date.accessioned | 2016-12-14T09:29:10Z | |
dc.date.available | 2016-12-14T09:29:10Z | |
dc.date.issued | 2016 | |
dc.identifier.citation | Molecular Pharmaceutics, American Chemical, 2016, vol. 7; 13; (3) p. 795-808 | es |
dc.identifier.issn | 1543-8384 | es |
dc.identifier.uri | http://uvadoc.uva.es/handle/10324/21697 | |
dc.description | Producción Científica | es |
dc.description.abstract | The search for new and biocompatible materials with high potential for improvement is a challenge in gene delivery applications. A cell type specific vector made of elastin- like recombinamer (ELR) and aptamers has been specifically designed for the intracellular delivery of therapeutic material for breast cancer therapy. A lysine-enriched ELR was constructed and complexed with plasmid DNA to give positively charged and stable polyplexes. Physical character- ization of these polyplexes showed a particle size of around 140 nm and a zeta potential of approximately +40 mV. The incorporation of MUC1-specific aptamers into the polyplexes resulted in a slight decrease in zeta potential but increased cell transfection specificity for MCF-7 breast cancer cells with respect to a MUC1-negative tumor line. After showing the transfection ability of this aptamer-ELR vector which is facilitated mainly by macropinocytosis uptake, we demonstrated its application for suicide gene therapy using a plasmid containing the gene of the toxin PAP-S. The strategy developed in this work about using ELR as polymeric vector and aptamers as supplier of specificity to deliver therapeutic material into MUC1-positive breast cancer cells shows promising potential and continues paving the way for ELRs in the biomedical field. | es |
dc.format.mimetype | application/pdf | es |
dc.language.iso | eng | es |
dc.publisher | American Chemical Society | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.subject | Cáncer-Terapias | es |
dc.title | Biocompatible ELR-Based Polyplexes Coated with MUC1 Specific Aptamers and Targeted for Breast Cancer Gene Therapy | es |
dc.type | info:eu-repo/semantics/article | es |
dc.identifier.doi | 10.1021/acs.molpharmaceut.5b00712 | es |
dc.relation.publisherversion | pubs.acs.org/molecularpharmaceutics | es |
dc.identifier.publicationfirstpage | 795 | es |
dc.identifier.publicationlastpage | 808 | es |
dc.identifier.publicationtitle | Molecular Pharmaceutics | es |
dc.identifier.publicationvolume | Vol. 7;13 (3) | es |
dc.peerreviewed | SI | es |
dc.description.project | Este trabajo forma parte de los Proyectos de Investigación financiados por la Comisión Europea a través del Fondo Social Europeo (FSE) y de la Consejería de Educación mediante el Fondo Europeo de Desarrollo Regional (ERDF), el MINECO (Proyectos MAT2013-41723-R, MAT2013-42473-R, PRI−PIBAR-2011-1403 y MAT2012-38043), la Junta de Castilla y León (Proyectos VA155A12, VA152A12, and VA244U13), el CIBER-BBN y el Instituto de Salud Carlos III mediante el Centro de Medicina Regenerativa y Terapia Celular de Castilla y León. | es |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
La licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 International